{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:12:46Z","timestamp":1793304766703,"version":"4.5.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007372","name":"Association Belge contre les Maladies Neuro-Musculaires","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007372","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004923","name":"AFM-T\u00e9l\u00e9thon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003134","name":"Fonds pour la Formation \u00e0 la Recherche dans l\u2019Industrie et dans l\u2019Agriculture","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003134","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002910","name":"F\u00e9d\u00e9ration Wallonie-Bruxelles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002910","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Duchenne muscular dystrophy (DMD) is the most common inherited human myopathy. Typically, the secondary process involving severe inflammation and necrosis exacerbate disease progression. Previously, we reported that the NLRP3 inflammasome complex plays a crucial role in this disorder. Moreover, pyroptosis, a form of programmed necrotic cell death, is triggered by NLRP3\n                      <jats:italic>via<\/jats:italic>\n                      gasdermin D (GSDMD). So far, pyroptosis has never been described either in healthy muscle or in dystrophic muscle. The aim of this study was to unravel the role of NLRP3 inflammasome in DMD and explore a potentially promising treatment with MCC950 that selectively inhibits NLRP3.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Four\u2010week\u2010old mdx mice (\n                      <jats:italic>n<\/jats:italic>\n                      =6 per group) were orally treated for 2 months with MCC950 (mdx\u2010T), a highly potent, specific, small-molecule inhibitor of NLRP3, and compared with untreated (mdx) and wild-type (WT) mice.\n                      <jats:italic>In vivo<\/jats:italic>\n                      functional tests were carried out to measure the global force and endurance of mice.\n                      <jats:italic>Ex vivo<\/jats:italic>\n                      biochemical and molecular analyses were performed to evaluate the pathophysiology of the skeletal muscle. Finally,\n                      <jats:italic>in vitro<\/jats:italic>\n                      tests were conducted on primary cultures of DMD human myotubes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After MCC950 treatment, mdx mice exhibited a significant reduction of inflammation, macrophage infiltration and oxidative stress (-20 to -65%,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt;0.05\n                      <jats:italic>vs<\/jats:italic>\n                      untreated mdx). Mdx\u2010T mice displayed considerably less myonecrosis (-54%,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt;0.05\n                      <jats:italic>vs<\/jats:italic>\n                      mdx) and fibrosis (-75%,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt;0.01\n                      <jats:italic>vs<\/jats:italic>\n                      mdx). Moreover, a more mature myofibre phenotype, characterized by larger-sized fibres and higher expression of mature myosin heavy chains 1 and 7 was observed. Mdx-T also exhibited enhanced force and resistance to fatigue (+20 to 60%,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt;0.05 or less). These beneficial effects resulted from MCC950 inhibition of both active caspase-1 (-46%,\n                      <jats:italic>P=<\/jats:italic>\n                      0.075) and cleaved gasdermin D (N-GSDMD) (-42% in medium-sized-fibres,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt;0.001). Finally, the anti-inflammatory action and the anti-pyroptotic effect of MCC950 were also recapitulated in DMD human myotubes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Specific inhibition of the NLRP3 inflammasome can significantly attenuate the dystrophic phenotype. A novel finding of this study is the overactivation of GSDMD, which is hampered by MCC950. This ultimately leads to less inflammation and pyroptosis and to a better muscle maturation and function. Targeting NLRP3 might lead to an effective therapeutic approach for a better management of DMD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2022.1049076","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T01:26:54Z","timestamp":1670376414000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Inhibiting the inflammasome with MCC950 counteracts muscle pyroptosis and improves Duchenne muscular dystrophy"],"prefix":"10.3389","volume":"13","author":[{"given":"Nicolas","family":"Dubuisson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda A.","family":"Davis-L\u00f3pez de Carrizosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Versele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille M.","family":"Selvais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Noel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Y. D.","family":"Van den Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia M.","family":"Brichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Abou-Samra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12531","article-title":"Adiporon, a new therapeutic prospect for duchenne muscular dystrophy","volume":"11","author":"Abou-Samra","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12915-018-0501-z","article-title":"Downregulation of the Nlrp3 inflammasome by adiponectin rescues duchenne muscular dystrophy","volume":"16","author":"Boursereau","year":"2018","journal-title":"BMC Biol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1172\/jci30556","article-title":"Interplay of Ikk\/Nf-kappab signaling in macrophages and myofibers promotes muscle degeneration in duchenne muscular dystrophy","volume":"117","author":"Acharyya","year":"2007","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cells10113023","article-title":"Walking down skeletal muscle lane: From inflammasome to disease","volume":"10","author":"Dubuisson","year":"2021","journal-title":"Cells"},{"key":"B6","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrd.2018.97","article-title":"Targeting the Nlrp3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat Rev Drug Discovery"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2016.10.004","article-title":"Pyroptosis: Gasdermin-mediated programmed necrotic cell death","volume":"42","author":"Shi","year":"2017","journal-title":"Trends Biochem Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the Nlrp3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-019-0278-6","article-title":"Mcc950 closes the active conformation of Nlrp3 to an inactive state","volume":"15","author":"Tapia-Abell\u00e1n","year":"2019","journal-title":"Nat Chem Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-019-0277-7","article-title":"Mcc950 directly targets the Nlrp3 atp-hydrolysis motif for inflammasome inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nat Chem Biol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1161\/atvbaha.117.309575","article-title":"Nlrp3 inflammasome inhibition by Mcc950 reduces atherosclerotic lesion development in apolipoprotein e-deficient mice-brief report","volume":"37","author":"van der Heijden","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"8618","DOI":"10.1038\/s41598-018-26775-w","article-title":"Mcc950, a specific small molecule inhibitor of Nlrp3 inflammasome attenuates colonic inflammation in spontaneous colitis mice","volume":"8","author":"Perera","year":"2018","journal-title":"Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.01.035","article-title":"Nlrp3 inflammasome inhibition with Mcc950 improves diabetes-mediated cognitive impairment and vasoneuronal remodeling after ischemia","volume":"142","author":"Ward","year":"2019","journal-title":"Pharmacol Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.02.016","article-title":"The selective Nlrp3 inflammasome inhibitor Mcc950 alleviates cholestatic liver injury and fibrosis in mice","volume":"70","author":"Qu","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10753-016-0449-5","article-title":"Activation of the Nlrp3 inflammasome is associated with valosin-containing protein myopathy","volume":"40","author":"Nalbandian","year":"2017","journal-title":"Inflammation"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1023\/a:1005545325254","article-title":"Understanding dystrophinopathies: An inventory of the structural and functional consequences of the absence of dystrophin in muscles of the mdx mouse","volume":"20","author":"Gillis","year":"1999","journal-title":"J Muscle Res Cell Motil"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.03.035","article-title":"An Nlrp3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice","volume":"90","author":"Ludwig-Portugall","year":"2016","journal-title":"Kidney Int"},{"key":"B18","unstructured":"Van PuttenM\n          The use of hanging wire tests to monitor muscle strength and condition over time"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1038\/s41467-020-16043-9","article-title":"N-gsdmd trafficking to neutrophil organelles facilitates il-1\u03b2 release independently of plasma membrane pores and pyroptosis","volume":"11","author":"Karmakar","year":"2020","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","first-page":"12447","DOI":"10.1038\/s41598-020-69018-7","article-title":"Mouse Cd163 deficiency strongly enhances experimental collagen-induced arthritis","volume":"10","author":"Svendsen","year":"2020","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13395-018-0171-0","article-title":"Musclej: A high-content analysis method to study skeletal muscle with a new Fiji tool","volume":"8","author":"Mayeuf-Louchart","year":"2018","journal-title":"Skelet Muscle"},{"key":"B22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13395-015-0051-9","article-title":"Involvement of adiponectin in the pathogenesis of dystrophinopathy","volume":"5","author":"Abou-Samra","year":"2015","journal-title":"Skeletal Muscle"},{"key":"B23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ab.2019.03.010","article-title":"Ponceau s waste: Ponceau s staining for total protein normalization","volume":"575","author":"Sander","year":"2019","journal-title":"Anal Biochem"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1038\/s41467-018-06057-9","article-title":"Necroptosis mediates myofibre death in dystrophin-deficient mice","volume":"9","author":"Morgan","year":"2018","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.150","article-title":"Regulation of muscle growth and regeneration by the immune system","volume":"17","author":"Tidball","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13395-015-0046-6","article-title":"Developmental myosins: Expression patterns and functional significance","volume":"5","author":"Schiaffino","year":"2015","journal-title":"Skelet Muscle"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880090108","article-title":"Fetal myosin immunoreactivity in human dystrophic muscle","volume":"9","author":"Schiaffino","year":"1986","journal-title":"Muscle Nerve"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051297","article-title":"Mechanisms regulating muscle regeneration: Insights into the interrelated and time-dependent phases of tissue healing","volume":"9","author":"Forcina","year":"2020","journal-title":"Cells"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20172222","article-title":"Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity","volume":"215","author":"Boucher","year":"2018","journal-title":"J Exp Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddu535","article-title":"Utrophin a is essential in mediating the functional adaptations of mdx mouse muscle following chronic ampk activation","volume":"24","author":"Al-Rewashdy","year":"2015","journal-title":"Hum Mol Genet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2012.06.003","article-title":"Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of duchenne muscular dystrophy","volume":"1","author":"Gordon","year":"2013","journal-title":"Clin Nutr"},{"key":"B32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1242\/dmm.018424","article-title":"Animal models of duchenne muscular dystrophy: From basic mechanisms to gene therapy","volume":"8","author":"McGreevy","year":"2015","journal-title":"Dis Model Mech"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.090058","article-title":"Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle","volume":"176","author":"Rawat","year":"2010","journal-title":"Am J Pathol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118069","article-title":"Genetic disruption of the inflammasome adaptor asc has minimal impact on the pathogenesis of duchenne muscular dystrophy in mdx mice","volume":"257","author":"Lau","year":"2020","journal-title":"Life Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/muscles1010008","article-title":"Does the pathogenic sequence of skeletal muscle degeneration in duchenne muscular dystrophy begin and end with unrestrained satellite cell activation","volume":"1","author":"Carlson","year":"2022","journal-title":"Muscles"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1113\/expphysiol.2010.056713","article-title":"The role of branched fibres in the pathogenesis of duchenne muscular dystrophy","volume":"96","author":"Chan","year":"2011","journal-title":"Exp Physiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1113\/expphysiol.2009.052019","article-title":"Branched fibres in old dystrophic mdx muscle are associated with mechanical weakening of the sarcolemma, abnormal Ca2+ transients and a breakdown of Ca2+ homeostasis during fatigue","volume":"95","author":"Head","year":"2010","journal-title":"Exp Physiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901363","article-title":"Cutting edge: Nf-kappab activating pattern recognition and cytokine receptors license Nlrp3 inflammasome activation by regulating Nlrp3 expression","volume":"183","author":"Bauernfeind","year":"2009","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0103-5","article-title":"Duchenne muscular dystrophy awaits gene therapy","volume":"37","author":"Jones","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12245","article-title":"Recent developments in duchenne muscular dystrophy: Facts and numbers","volume":"8","author":"Walter","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B41","doi-asserted-by":"publisher","first-page":"Cd003725","DOI":"10.1002\/14651858.CD003725.pub4","article-title":"Corticosteroids for the treatment of duchenne muscular dystrophy","volume":"2016","author":"Matthews","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B42","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2174\/187153012799279045","article-title":"Glucocorticoid analogues: Potential therapeutic alternatives for treating inflammatory muscle diseases","volume":"12","author":"Reeves","year":"2012","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171419","article-title":"Identification of a selective and direct Nlrp3 inhibitor to treat inflammatory disorders","volume":"214","author":"Jiang","year":"2017","journal-title":"J Exp Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(20)30065-5","article-title":"Dapansutrile, an oral selective Nlrp3 inflammasome inhibitor, for treatment of gout flares: An open-label, dose-adaptive, proof-of-Concept, phase 2a trial","volume":"2","author":"Kl\u00fcck","year":"2020","journal-title":"Lancet Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1049076\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T01:27:02Z","timestamp":1670376422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1049076\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,7]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2022.1049076"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1049076","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,7]]},"article-number":"1049076"}}